Send E-mail
  • Corestem inks W13b deal with Hanlim Pharm
    Corestem inks W13b deal with Hanlim Pharm
    Corestem (166480) has clinched a technology transfer deal worth 13 billion won (US$11.4 million) with Hanlim Pharm on a stem cell treatment for systemic lupus erythematosus, it said on July 26. The deal amounts to 19.4 percent of Corestem’s recent net worth.
From
Send to
Close Send

Corestem inks W13b deal with Hanlim Pharm

July 26, 2016 - 13:31 By 정민경
[DISCLOSURE] Corestem (166480) has clinched a technology transfer deal worth 13 billion won (US$11.4 million) with Hanlim Pharm on a stem cell treatment for systemic lupus erythematosus, it said on July 26. The deal amounts to 19.4 percent of Corestem’s recent net worth.
Most Popular